||ProHeart 6 is introduced in the United States.
||Decision is made to only use batches of technical material with undetectable residual solvents for manufacturing of product.
||1 of every 5 dogs on heartworm disease preventatives is receiving ProHeart 6 injections.5
||The FDA expresses concerns regarding consumer reports of adverse events. ProHeart 6 is voluntarily withdrawn from the U.S. market to further evaluate its safety profile.
||The ProHeart 6 safety profile is found to be similar to that of current oral heartworm preventatives.
||ProHeart 6 is reintroduced in the United States using a RiskMAP (Risk Minimization Action Plan).
||ProHeart 6 maintains a predictable, expected adverse event profile that remains consistent as product use steadily increases.
||The RiskMAP is revised, allowing use in healthy dogs older than 7 years, permitting administration by certified veterinary staff and removing a client consent signature requirement.
||Zoetis continues education on the proper use of ProHeart 6. More than 30,000 veterinarians and clinical staff have been certified to administer it.